Eli Lilly's (LLY) Taltz and Zepbound used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

Eli Lilly's recent trial results showing enhanced efficacy from combining Taltz and Zepbound for treating psoriasis in overweight adults could bolster its position in the competitive pharmaceuticals market.

Newsquawk StaffPublished On the live feed at 10 more headlines followed before this page went public
Newsquawk headlinesUTC

Garmin Ltd. (GRMN) Q4 2025 (USD): Adj. EPS 2.79 (exp. 2.40), Revenue 2.10bln (exp. 2.02bln), sees FY26 at 9.35 (exp. 8.78) and revenue 7.9bln (exp. 7.7bln)

Hungarian Foreign Minister says MoL has ordered 500k tonnes of crude, which will be sent to a Croatian port

Eli Lilly's (LLY) Taltz and Zepbound used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

Russian oil drilling has reportedly dropped to the lowest in three years in 2025

Slovakian refiner Slovnaft says it has ordered supplies that will allow operations at full capacity from April

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This promising outcome not only highlights innovation in their treatment portfolio but also may attract investor interest, reflecting positively on both the company's growth potential and overall sector outlook.

Related headlines

The whole workspace, free to try.

Try it free